Kyowa Hakko Kirin

The European Commission (EC) has revealed its decision to grant conditional marketing authorisation to Kyowa Kirin for Crysvita (burosumab) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children & adolescents Read more

Recipharm was informed on 20 September 2013 by the R&D-based pharmaceutical company Kyowa Hakko Kirin Co. Ltd. that the Abstral sublingual (under the tongue) tablet has been approved for manufacturing and marketing by Japan's Ministry of Health... Read more